2026 Neurotech Commercialization Workshop

CCNY, New York City, and On-Line via Zoom, August 3, 2026

Conference Facilitators
James Cavuoto, Editor and Publisher, Neurotech Reports James Cavuoto is editor and publisher of Neurotech Business Report and the founder of Neurotech Reports. He is the lead author of "The Market for Neurotechnology," and "The Market for Bioelectronic Medicine," two market research reports published by Neurotech Reports. Cavuoto was the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier, 2009), as well as articles in Neuromodulation, Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing. He is coauthor, with Jennifer French, of Bionic Pioneers: Brave Neurotech Users Blaze the Trail to New Therapies (Neurotech Press, 2014).
Jeremy Koff, Senior Consulting Editor, Neurotech Reports Mr. Koff is senior contributing editor for Neurotech Reports and president of Colibri Partners Inc., a strategic and marketing consulting firm with a primary focus in the medical device sector. The company offers services related to market and risk analysis, clinical and technology assessments, business plan development, business/financial modeling, and market research. Mr. Koff has nearly 20 years of global experience in the medical device industry with companies including Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc, and many others. His business plans have attracted tens of millions in start-up capital. Mr. Koff holds a Bachelor's degree in biology from Middlebury College, a Masters of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically-trained musician, supporter of the arts, and is a board member of the Fender Music Foundation.
Jo Jo Platt, Senior Contributing Editor, Neurotech Reports Jo Jo Platt brings more than 10 years experience as a neurotechnology consulant to Neurotech Reports. As the founder and president of Platt & Associates, she has helped leadership identify new opportunities, transform organizations, and build teams from the ground up. Most recently, she was a strategic development consultant for the Feinstein Institute for Medical Research, where she helped identify and establish strategic partnerships in the emerging field of bioelectronic medicine and was instrumental in the launch of the Center for Bioelectronic Medicine. Previously, Jo Jo communications director for eDigital, where she managed all internal and external communications and built braand recognition through tradeshows and consumer events. Platt holds a bachelor's degree in communication and media studies from National University. She is currently the finance chair for the IEEE Engineering in Medicine and Biology Neural Engineering 2019 meeting.

Conference Facilitators

James Cavuoto, Editor and Publisher, Neurotech Reports

James Cavuoto is editor and publisher of Neurotech Business Report and the founder of Neurotech Reports. He is the lead author of "The Market for Neurotechnology," and "The Market for Bioelectronic Medicine," two market research reports published by Neurotech Reports. Cavuoto was the founder of Micro Publishing Press, Inc., a publishing company that helped pioneer the market for electronic publishing, digital imaging, and computer graphics. He holds a degree in biomedical engineering from Case Western Reserve University, where he studied under pioneers in the field of functional electrical stimulation. He has also studied human factors engineering at University of Southern California in Los Angeles. Cavuoto spent three years as a member of the technical staff at Hughes Aircraft Company in Los Angeles, where he worked on simulation, training, and publication products produced for the U.S. Department of Defense. Cavuoto was an adjunct professor at Rochester Institute of Technology and the author of eight books on computer graphics, electronic publishing, and digital imaging. He is a member of the IEEE Engineering in Medicine and Biology Society. He has authored a chapter in the textbook Neuromodulation (Elsevier, 2009), as well as articles in Neuromodulation, Journal of Neural Engineering, Medical Device Daily, IEEE Spectrum, MX magazine, and the International Journal of Medical Marketing. He is coauthor, with Jennifer French, of Bionic Pioneers: Brave Neurotech Users Blaze the Trail to New Therapies (Neurotech Press, 2014).

Jeremy Koff, Senior Consulting Editor, Neurotech Reports

Mr. Koff is senior contributing editor for Neurotech Reports and president of Colibri Partners Inc., a strategic and marketing consulting firm with a primary focus in the medical device sector. The company offers services related to market and risk analysis, clinical and technology assessments, business plan development, business/financial modeling, and market research. Mr. Koff has nearly 20 years of global experience in the medical device industry with companies including Advanced Bionics Corp., Boston Scientific, MiniMed Inc., Bioness Inc, and many others. His business plans have attracted tens of millions in start-up capital. Mr. Koff holds a Bachelor's degree in biology from Middlebury College, a Masters of Public Affairs from Indiana University, and an MBA from UCLA. He is an active classically-trained musician, supporter of the arts, and is a board member of the Fender Music Foundation.

Jo Jo Platt, Senior Contributing Editor, Neurotech Reports

Jo Jo Platt brings more than 10 years experience as a neurotechnology consulant to Neurotech Reports. As the founder and president of Platt & Associates, she has helped leadership identify new opportunities, transform organizations, and build teams from the ground up. Most recently, she was a strategic development consultant for the Feinstein Institute for Medical Research, where she helped identify and establish strategic partnerships in the emerging field of bioelectronic medicine and was instrumental in the launch of the Center for Bioelectronic Medicine. Previously, Jo Jo communications director for eDigital, where she managed all internal and external communications and built braand recognition through tradeshows and consumer events. Platt holds a bachelor's degree in communication and media studies from National University. She is currently the finance chair for the IEEE Engineering in Medicine and Biology Neural Engineering 2019 meeting.

Investor Advisors
Josh Schulman, Ph.D., Chief Scientist, Corundum Neuroscience Josh is the Chief Scientist at Corundum Neuroscience. Before joining CNS, he led Partnerships and Innovation at Genetika+, a startup working on tools for successful drug development and personalized treatment of psychiatric disorders. Prior to that, he led regulatory and clinical affairs at MaxQ AI and helped bring one of the first radiology AI applications to the market while working closely with FDA to develop policy on AI and Software as a Medical Device (SaMD). He continues to be active in helping develop standards and policy for medical devices and has served on industry groups addressing the use artificial intelligence and cloud computing for healthcare. For over a decade, Josh has also worked with academic technology transfer companies, small businesses, and investors across the medical device and pharma industries as well as lecturing and assisting team projects in Hebrew University’s Biodesign program. Earlier in his career, Josh worked in both large and small pharmaceutical and medical device companies, including regulatory affairs at Omrix Biopharmaceuticals. Josh’s scientific and management training began with a PhD in neuroscience which used magnetoencephalography to study the impact of different brain activity modes on normal and disease states. Following a postdoc on brain biomarker development, he worked with government agencies on science strategy and program management.
Gadareth Higgs, Ph.D., Partner, Advantary Capital Partners Gadareth Higgs is a seasoned expert with more than 15 years of postgraduate experience in bioinformatics, consulting, and healthcare. As a Due Diligence Analyst Partner at Advantary Capital Partners, he contributes to the firm’s mission of combining deep operational expertise with strategic investment insight to help portfolio companies thrive. Through Higgs Insights, he has helped startups double investor interest, raise funding ($200k–$7M), prepare for pitches in only four days, and secure a $1M LP commitment. His previous experience includes leading precision oncology, biotechnology, and healthcare consulting initiatives at ConcertAI and McKinsey, where he guided large-scale transformations and due diligence for healthcare acquisitions exceeding $1B. Holding a Ph.D. in Molecular, Cellular, and Developmental Biology from Yale University, Dr. Higgs brings rigorous analytical discipline and a passion for data-driven decision-making to Advantary’s investment process. His work bridges science, strategy, and finance—advancing innovations that improve patient outcomes and redefine growth in the life sciences.
Adam Caplan, Founder and General Partner, Jumpspace Ventures Adam Caplan is the the founder of Jumpspace Ventures, a venture firm focused on breakthrough innovations in neuroscience and human-machine interfaces. With a portfolio of companies advancing brain-computer interfaces, neuromodulation, and neural diagnostics, Adam is passionate about technologies that record from or stimulate the brain and nervous system to treat serious conditions like motor neuron disease, epilepsy, and stroke. Prior to Jumpspace, Adam co-founded ID8 Investments (a diversified venture capital firm), Facteus (a leader in alternative data for financial markets), and Artisan Council (a digital marketing agency). Prior to being an entrepreneur, Adam was investment banker with Morgan Stanley. He now combines entrepreneurial and financial experience with deep conviction in the future of neurotech and human augmentation.

Investor Advisors

Josh Schulman, Ph.D., Chief Scientist, Corundum Neuroscience

Josh is the Chief Scientist at Corundum Neuroscience. Before joining CNS, he led Partnerships and Innovation at Genetika+, a startup working on tools for successful drug development and personalized treatment of psychiatric disorders. Prior to that, he led regulatory and clinical affairs at MaxQ AI and helped bring one of the first radiology AI applications to the market while working closely with FDA to develop policy on AI and Software as a Medical Device (SaMD). He continues to be active in helping develop standards and policy for medical devices and has served on industry groups addressing the use artificial intelligence and cloud computing for healthcare. For over a decade, Josh has also worked with academic technology transfer companies, small businesses, and investors across the medical device and pharma industries as well as lecturing and assisting team projects in Hebrew University’s Biodesign program. Earlier in his career, Josh worked in both large and small pharmaceutical and medical device companies, including regulatory affairs at Omrix Biopharmaceuticals. Josh’s scientific and management training began with a PhD in neuroscience which used magnetoencephalography to study the impact of different brain activity modes on normal and disease states. Following a postdoc on brain biomarker development, he worked with government agencies on science strategy and program management.

Gadareth Higgs, Ph.D., Partner, Advantary Capital Partners

Gadareth Higgs is a seasoned expert with more than 15 years of postgraduate experience in bioinformatics, consulting, and healthcare. As a Due Diligence Analyst Partner at Advantary Capital Partners, he contributes to the firm’s mission of combining deep operational expertise with strategic investment insight to help portfolio companies thrive. Through Higgs Insights, he has helped startups double investor interest, raise funding ($200k–$7M), prepare for pitches in only four days, and secure a $1M LP commitment. His previous experience includes leading precision oncology, biotechnology, and healthcare consulting initiatives at ConcertAI and McKinsey, where he guided large-scale transformations and due diligence for healthcare acquisitions exceeding $1B. Holding a Ph.D. in Molecular, Cellular, and Developmental Biology from Yale University, Dr. Higgs brings rigorous analytical discipline and a passion for data-driven decision-making to Advantary’s investment process. His work bridges science, strategy, and finance—advancing innovations that improve patient outcomes and redefine growth in the life sciences.

Adam Caplan, Founder and General Partner, Jumpspace Ventures

Adam Caplan is the the founder of Jumpspace Ventures, a venture firm focused on breakthrough innovations in neuroscience and human-machine interfaces. With a portfolio of companies advancing brain-computer interfaces, neuromodulation, and neural diagnostics, Adam is passionate about technologies that record from or stimulate the brain and nervous system to treat serious conditions like motor neuron disease, epilepsy, and stroke. Prior to Jumpspace, Adam co-founded ID8 Investments (a diversified venture capital firm), Facteus (a leader in alternative data for financial markets), and Artisan Council (a digital marketing agency). Prior to being an entrepreneur, Adam was investment banker with Morgan Stanley. He now combines entrepreneurial and financial experience with deep conviction in the future of neurotech and human augmentation.